TrialAnnals of hematology2025

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Cécile Tomowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.